ReviewGlobal challenges (Hoboken, NJ)2025
Gadolinium-Based Contrast Agents (GBCAs) for MRI: A Benefit-Risk Balance Analysis from a Chemical, Biomedical, and Environmental Point of View.
Review in Global challenges (Hoboken, NJ), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Rare Earth Elements in Testicular Function: Current Knowledge and Future Directions.International journal of molecular sciences · 2026Review
- Article
- Assessing Patient Awareness and Misconceptions Regarding MRI Radiation Risks in China: A Questionnaire Study.Nursing open · 2026Article
- Multi-Sequence Guided Generation of Contrast-Enhanced Magnetic Resonance Imaging Using Diffusion Models.Bioengineering (Basel, Switzerland) · 2026Article
- Gadolinium-Based Contrast Agents and the Theater of Safety.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Magnetite nanodiscs as vortex-enhanced MRI contrast agents: a novel approach in medical imaging.Nanoscale advances · 2026Article
- Gadolinium Pollution-A Future Forward Perspective on Human and Environmental Impact.Magnetic resonance in medicine · 2026Review
- Knowledge-Guided Framework for Synthesizing Contrast-Dependent Data from Multi-Sequence Non-Contrast MRI.Diagnostics (Basel, Switzerland) · 2026Article
- Hybrid FeInternational journal of molecular sciences · 2026Article
- Aortic dissection as a disease of vascular wall homeostasis: integrating vasa vasorum-inflammation-metabolism axis for mechanistic insight and clinical translation.Frontiers in immunology · 2026Review
- Gadolinium toxicity: mechanisms, clinical manifestations, and nanoparticle role.Archives of toxicology · 2025Review
- Current Status and Future Aspects of Gadolinium Oxide Nanoparticles as Positive Magnetic Resonance Imaging Contrast Agents.Nanomaterials (Basel, Switzerland) · 2025Review
- Nanoparticle-enabled molecular imaging diagnosis of osteoarthritis.Materials today. Bio · 2025Review
- Paramagnetic and Luminescent Properties of Gd(III)/Eu(III) Ascorbate Coordination Polymers.Molecules (Basel, Switzerland) · 2025Article
- Gadolinium-Based Contrast Agents (GBCAs) for MRI: A Benefit-Risk Balance Analysis from a Chemical, Biomedical, and Environmental Point of View.Global challenges (Hoboken, NJ) · 2025Review
- Exosome tracking by magnetic resonance imaging.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gadolinium-based contrast agents (GBCAs) have revolutionized medical imaging, enhancing the accuracy and diagnostic value of magnetic resonance imaging (MRI). The increasing use of GBCAs has raised concerns about the release of gadolinium (Gd)(III) into the environment and potential risks for human health. Initially, multiple administrations of GBCAs were associated only with nephrogenic system fibrosis disease in individuals with impaired kidney function. Even if the Gd(III) retention in tissues has not yet been correlated with any specific disease, caution is required for the extensive use of GBCAs. The concerns related to the employment of GBCAs, due to the possible deposition and retention, should be extended also to healthy individuals without renal impairments. To ensure the well-being of patients, there is a need to develop even more stable and better-performing GBCAs, new MRI approaches requiring lower doses of GBCAs and, finally, innovative methods for recovering Gd(III) from both patients' urines and the environment. This can have strong advantages for human health and for environmental sustainability, also considering Gd(III) scarcity, being a rare earth element, and the shared guideline to reduce, as much as possible, the use of rare metals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.